BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $3,654,000 | +25.0% | 359,300 | -8.4% | 0.00% | +50.0% |
| Q4 2020 | $2,923,000 | +112.9% | 392,309 | -1.9% | 0.00% | +100.0% |
| Q3 2020 | $1,373,000 | -16.8% | 399,809 | +15.4% | 0.00% | -50.0% |
| Q2 2020 | $1,651,000 | +149.0% | 346,467 | +4.5% | 0.00% | +100.0% |
| Q1 2020 | $663,000 | -17.3% | 331,655 | +42.7% | 0.00% | 0.0% |
| Q4 2019 | $802,000 | +99.5% | 232,455 | +65.7% | 0.00% | – |
| Q3 2019 | $402,000 | -11.3% | 140,314 | +17.3% | 0.00% | -100.0% |
| Q2 2019 | $453,000 | -50.5% | 119,621 | +6.3% | 0.00% | 0.0% |
| Q1 2019 | $916,000 | -23.7% | 112,521 | -24.3% | 0.00% | -50.0% |
| Q4 2018 | $1,200,000 | +31.3% | 148,673 | +24.1% | 0.00% | +100.0% |
| Q3 2018 | $914,000 | +45.8% | 119,821 | +9.5% | 0.00% | 0.0% |
| Q2 2018 | $627,000 | +11.2% | 109,400 | -7.5% | 0.00% | 0.0% |
| Q1 2018 | $564,000 | -2.9% | 118,300 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $581,000 | -6.3% | 118,300 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $620,000 | -5.8% | 118,300 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $658,000 | -33.8% | 118,300 | 0.0% | 0.00% | -50.0% |
| Q1 2017 | $994,000 | +27.3% | 118,300 | -4.1% | 0.00% | +100.0% |
| Q4 2016 | $781,000 | +43.6% | 123,400 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $544,000 | +45.1% | 123,400 | -6.5% | 0.00% | 0.0% |
| Q2 2016 | $375,000 | -2.6% | 132,000 | -3.1% | 0.00% | 0.0% |
| Q1 2016 | $385,000 | -74.2% | 136,200 | -5.7% | 0.00% | -50.0% |
| Q4 2015 | $1,491,000 | -9.5% | 144,500 | 0.0% | 0.00% | -33.3% |
| Q3 2015 | $1,647,000 | -23.6% | 144,500 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $2,157,000 | +21.5% | 144,500 | -10.0% | 0.00% | +50.0% |
| Q1 2015 | $1,775,000 | 0.0% | 160,500 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,775,000 | +25.6% | 160,500 | +11.1% | 0.00% | 0.0% |
| Q3 2014 | $1,413,000 | -23.3% | 144,500 | 0.0% | 0.00% | -33.3% |
| Q2 2014 | $1,842,000 | +34.8% | 144,500 | 0.0% | 0.00% | +50.0% |
| Q1 2014 | $1,366,000 | +25.1% | 144,500 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $1,092,000 | +3.8% | 144,500 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $1,052,000 | +363.4% | 144,500 | -1.4% | 0.00% | – |
| Q2 2013 | $227,000 | – | 146,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |